Tianyin Pharmaceutical Co, Inc, a manufacturer and supplier of modernized traditional Chinese medicine (TCM) based in Chengdu, China, has received approvals from the Chinese State Food and Drug Administration (SFDA) to produce Sanqi tablets in dosage form of 0.5 gram/tablet (SFDA approval number Z20093512) and Yinqiao Jiedu tablets in dosage form of 0.5 gram/tablet (SFDA approval number Z20093555).
Sanqi Tablets are a generic TCM that effectively treats traumatic injuries and stops bleeding without causing blood stasis, while also alleviating associated pain and reducing swelling. Sanqi is also used as a haemostatic for patients with internal bleeding or hemorrhagic diseases. According to Tianyin's market research and estimation, annual sales of Sanqi are approximately $73.5 million in China. Tianyin expects to gain a portion of the market share in orthopedic medicine through the production and marketing of Sanqi Tablets.
Yinqiao Jiedu Tablets are a generic TCM which are used mainly to treat acute respiratory system ailments, such as influenza and common cold. It is specifically used to clear the lungs and aid in function of the throat. Tianyin estimates that total annual sales of Yinqiao Jiedu Tablets are approximately $1.2 billion in China. Tianyin expects the demand of this product will increase during the wintertime flu season and that our introduction of this product will increase the Company's market share in the flu medicine market.
"We are very pleased to receive approvals for our Sanqi Tablets and Yinqiao Jiedu Tablets from the Chinese SFDA. These products further complement our product portfolio and create additional revenue opportunities for medical indications which we have not previously addressed," Dr Jiang, chairman and CEO of Tianyin Pharmaceutical Co, Inc, commented. "We will produce both drugs in our new facility which just passed Sichuan provincial FDA inspection, a key component of GMP certification, in July. We believe the facility meets all GMP standards and we expect to receive certification in the very near term, a milestone which will significantly increase our capacity and enable us to achieve our growth objectives."
Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine (TCM) in China.